The FDA has issued draft guidance recommending that all biosimilar medications be designated as interchangeable with their reference products upon initial FDA approval. A 60-day review and comment period of the draft guidance is now open, and the ACR will soon be submitting comments.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

How Rheumatologists Can Integrate Shared Decision Making into Clinical Practice
Experts identify barriers to shared decision making in rheumatology & offer actionable tools to integrate SDM into practice for better patient outcomes.

New Insights into the Management of Interstitial Lung Disease
Discover the latest ILD management strategies for RA, SSc & myositis, plus expert guidance on pregnancy & defining progressive pulmonary fibrosis.
MIPS, MVPs & RISE: The Scoop on Quality Reporting for 2026
ACR experts break down MIPS, MVPs & the RISE registry, helping clinicians understand quality reporting requirements for 2026 & beyond.

ACR Releases New Guideline for Management of SLE at ACR 2025
Updating the last iteration in 1999, the new ACR Guideline for Management of SLE was unveiled at ACR Convergence 2025, providing rheumatologists an organ-based approach for therapeutic options for specific lupus manifestations.

3 AC&R Study Summaries: RA & Frailty, Hydroxychloroquine Can Protect Kidneys in Lupus Nephritis, & PT for Knee OA
Research on PT for knee OA, HCQ’s protective role in lupus nephritis & the link between RA disease activity & frailty.

Why Target B Cells in SSc-ILD?
In a recent Arthritis & Rheumatology review article, three experts discuss the use of immunosuppressants to target B cells in a patient with systemic sclerosis-interstitial lung disease.

Rheuminations: Address Ableism, Improve Care for All Patients
Ableism—discrimination against those with disabilities—distorts diagnostic reasoning & erodes patient trust. How can rheumatologists address this bias?

New Rheumatoid Arthritis Risk Stratification Criteria Released
New EULAR/ACR criteria help stratify RA risk in patients with arthralgia. Learn how these criteria guide earlier interventions & improve trial rigor.

The Microbiome’s Impact on Rheumatoid Arthritis & Drug Response
The gut microbiome may trigger RA & predict methotrexate response. ACR Convergence 2025 experts discuss pathogenesis & drug efficacy.
- 1
- 2
- 3
- …
- 250
- Next Page »
